Angiogenesis in cancer and other diseases
The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases. Concentrated efforts in this area of research are leading to the discovery of a growing number of pro- and anti-angiogenic molecules, some of which are already in clinical trials. The complex interactions among these molecules and how they affect vascular structure and function in different environments are now beginning to be elucidated. This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of vascularization is one of the landmarks of tumor environments [57,180].”
From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [180]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162 · cited 1×
“We now know there are various molecular players involved in these different mechanisms of vascular growt”
BackgroundSelf-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Self-citationO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“However, caution is warranted as these hypoxia-inducible factors could also control cell deat”
BackgroundSelf-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationCancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054 · cited 1×
“In vivo selection of phage display libraries has recently yielded peptides (for example, amino-acid sequences RGD and NGR) that preferentially recognize vessels in subcutaneous tumours in mic”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Self-citationHelmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Self-citation
Research works printed but not linked: 8
- Greenblatt, M. & Shubik, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparant chamber technique. J. Natl Cancer Inst. 41, 111–124 (1968).
- Ehrmann, R. L. & Knoth, M. Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J. Natl Cancer Inst. 41, 1329 –1341 (1968).
- Folkman, J. in Cancer Medicine (eds Holland, J. F. et al.) 132– 152 (Decker, Ontario, Canada, 2000).
- Chang, Y. S. et al. Abundance of neoplastic cells in vessel walls of human tumor xenografts. Proc. Am. Assoc. Cancer Res. (in the press).
- Seljelid, R., Jozefowski, S. & Sveinbjornsson, B. Tumor stroma. Anticancer Res. 19, 4809–4822 (1999).
- Buschmann, I. & Schaper, W. The pathophysiology of the collateral circulation (arteriogenesis). J. Pathol. 190, 338–342 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<338::aid-path594>3.0.co;2-7
- Carmeliet, P. & Collen, D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190, 387–405 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<387::aid-path595>3.0.co;2-r
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1alpha/HRE/VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. (in the press).
Cited by
Items 801–900 of 1,084
Wu, Y., Li, Y.-Y., Matsushima, K., Baba, T., & Mukaida, N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6384 · Cited by 166
Khoo, B. L., Grenci, G., Lim, Y. B., Lee, S. C., Han, J., & Lim, C. T. (2018) · Nature Protocols · doi:10.1038/nprot.2017.125 · Cited by 172
T lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Liu, Y., Chan, J. K. Y., & Teoh, S.-H. (2015) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1617 · Cited by 167
“Tissues rely on blood vessels within close proximity of~100-200 mm to supply sufficient nutrients and oxygen (Carmeliet and Jain, 2000).”
BackgroundIn vitro 3D collective sprouting angiogenesis under orchestrated ANG-1 and VEGF gradients
Shin, Y., Jeon, J. S., Han, S., Jung, G.-S., Shin, S., Lee, S.-H., Sudo, R., Kamm, R. D., & Chung, S. (2011) · Lab on a Chip · doi:10.1039/c1lc20039a · Cited by 166
Ding, S., Merkulova-Rainon, T., Han, Z. C., & Tobelem, G. (2003) · Blood · doi:10.1182/blood-2002-06-1731 · Cited by 172
“Thus, the H-190 antibody may (1) block the HGF/c-met interaction; (2) generate steric hindrance thus preventing the dimerization of 2 c-met molecules (a process that appears to be critical for the activation of c-met 33); and (3) prevent the formation of supramolecular complexes between c-met and some other proteins.”
BackgroundDendritic Cells and Tumor Microenvironment: A Dangerous Liaison
Fricke, I., & Gabrilovich, D. I. (2006) · Immunological Investigations · doi:10.1080/08820130600803429 · Cited by 165
Parathath, S., Mick, S. L., Feig, J. E., Joaquin, V., Grauer, L., Habiel, D. M., Gassmann, M., Gardner, L. B., & Fisher, E. A. (2011) · Circulation Research · doi:10.1161/circresaha.111.246363 · Cited by 166
Garrett, T. A., Van Buul, J. D., & Burridge, K. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.05.027 · Cited by 164
“For example, in tumor angiogenesis, VEGF enhances tumor growth by inducing the migration and organization of surrounding endothelial cells into nascent blood vessels [1,2].”
BackgroundKondo, S. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.769 · Cited by 172
“This process is regulated by a balance between positive and negative angiogenic factors, and is disregulated in various diseases, especially in cancers ( 1 ,3,4).”
BackgroundEpithelial-Mesenchymal Transition (EMT) as a Therapeutic Target
Jonckheere, S., Adams, J., De Groote, D., Campbell, K., Berx, G., & Goossens, S. (2022) · Cells Tissues Organs · doi:10.1159/000512218 · Cited by 171
“This process has a higher efficiency than the formation of secondary metastases as the neovasculature is leaky at the primary tumour, and there is no need to adapt to the new microenvironment [Carmeliet and Jain, 2000].”
BackgroundGalldiks, N., Rapp, M., Stoffels, G., Fink, G. R., Shah, N. J., Coenen, H. H., Sabel, M., & Langen, K.-J. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2251-4 · Cited by 171
“The resultant high interstitial pressure produces hypoxia and a growth advantage for tumour cells [32].”
BackgroundEndothelial Progenitor Cells for the Vascularization of Engineered Tissues
Peters, E. B. (2018) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2017.0127 · Cited by 171
“Without perfusion from embedded microvasculature, the thickness of in vitro engineered tissue constructs is limited to the oxygen diffusional limit, which is approximately 200 μm.(8,9,10) In addition, host vessel ingrowth is limited to tens of microns per day, requiring several days to weeks to fully vascularize a sev…”
White, R. R., Shan, S., Rusconi, C. P., Shetty, G., Dewhirst, M. W., Kontos, C. D., & Sullenger, B. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0831159100 · Cited by 171
Therapeutic application of anti-angiogenic nanomaterials in cancers
Mukherjee, S., & Patra, C. R. (2016) · Nanoscale · doi:10.1039/c5nr07887c · Cited by 169
Paskeh, M. D. A., Ghadyani, F., Hashemi, M., Abbaspour, A., Zabolian, A., Javanshir, S., Razzazan, M., Mirzaei, S., Entezari, M., Goharrizi, M. A. S. B., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106553 · Cited by 177
Hierarchical microimaging for multiscale analysis of large vascular networks
Heinzer, S., Krucker, T., Stampanoni, M., Abela, R., Meyer, E. P., Schuler, A., Schneider, P., & Müller, R. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.03.043 · Cited by 170
“Because pathological angiogenesis is a disease hallmark (Carmeliet and Jain, 2000), resolving microvasculature is of particular interest.”
BackgroundAnti-Angiogenic Peptides for Cancer Therapeutics
V. Rosca, E., E. Koskimaki, J., G. Rivera, C., B. Pandey, N., P. Tamiz, A., & S. Popel, A. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111796117300 · Cited by 170
“These interactions occur through secreted factors such as VEGF, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and angiopoietins, as well as through cellextracellular matrix (ECM) interactions [5-7].”
BackgroundRepulsive axon guidance molecule Slit3 is a novel angiogenic factor
Zhang, B., Dietrich, U. M., Geng, J.-G., Bicknell, R., Esko, J. D., & Wang, L. (2009) · Blood · doi:10.1182/blood-2008-12-193326 · Cited by 162
Martinet, L., Filleron, T., Guellec, S. L., Rochaix, P., Garrido, I., & Girard, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300872 · Cited by 175
“B lood vessels and tumor angiogenesis are generally associated with tumor growth and poor clinical outcome of cancer patients (1, 2).”
BackgroundAgarwal, R., Jurney, P., Raythatha, M., Singh, V., Sreenivasan, S. V., Shi, L., & Roy, K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500441 · Cited by 169
Kostka, G., Giltay, R., Bloch, W., Addicks, K., Timpl, R., Fässler, R., & Chu, M.-L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.7025-7034.2001 · Cited by 169
“Angiogenesis is controlled by various cytokines including vascular endothelial growth factors (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and transforming growth factor , which transmit their signals through several receptor kinases (7, 12, 22, 45).”
BackgroundPlasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Stefansson, S., McMahon, G., Petitclerc, E., & Lawrence, D. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454621 · Cited by 169
“Remodeling of the extracellular matrix has been suggested to be essential for the migratory events required for angiogenesis [73] and since uPA is localized to the leading edge of migrating cells [74], it would appear that regulation of uPA activity by PAI-1 would lead to an inhibition of angiogenesis and hence tumor…”
BackgroundSphingolipid Mediators in Cardiovascular Cell Biology and Pathology
Levade, T., Augé, N., Veldman, R. J., Cuvillier, O., Nègre-Salvayre, A., & Salvayre, R. (2001) · Circulation Research · doi:10.1161/hh2301.100350 · Cited by 169
Eetezadi, S., Ekdawi, S. N., & Allen, C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.001 · Cited by 166
Vasculature-On-A-Chip for In Vitro Disease Models
Kim, S., Kim, W., Lim, S., & Jeon, J. (2017) · Bioengineering · doi:10.3390/bioengineering4010008 · Cited by 157
Deep learning for fast denoising filtering in ultrasound localization microscopy
Yu, X., Luan, S., Lei, S., Huang, J., Liu, Z., Xue, X., Ma, T., Ding, Y., & Zhu, B. (2023) · Physics in Medicine and Biology · doi:10.1088/1361-6560/acf98f · Cited by 169
Zhang, R., Xu, Y., Ekman, N., Wu, Z., Wu, J., Alitalo, K., & Min, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310678200 · Cited by 163
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells
von Haussen, J., Koczulla, R., Shaykhiev, R., Herr, C., Pinkenburg, O., Reimer, D., Wiewrodt, R., Biesterfeld, S., Aigner, A., Czubayko, F., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.014 · Cited by 161
Bertl, E., Bartsch, H., & Gerhäuser, C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0324 · Cited by 169
“Angiogenesis is a physiologic process relevant for tissue growth, remodeling, and wound healing but is also a prerequisite for tumor growth and metastasis (21).”
BackgroundJi, R.-C. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9026-y · Cited by 168
“VEGFR-3 (788 bp) forward and reverse are 5′-TTG GCATCA ATA AAG GCA G-3′ and 5′-CTG CGT GGTGTACACCTTA-3′;Prox-1 (674 bp) forward and reverse are 5′GTG TGC AGATGC CTA GTT CCA CA-3′ and 5′-TAC TGG TGA CTC CAT CAT TGA TG-3′. Both the VEGFR-3 and Prox-1 are expressed in the different tumor tissues Fig. 3 Electron micrograp…”
BackgroundInfluentialEngineering vascularised tissues in vitro
Institute for BioMedical Technology, D. O. T. R., Rivron, N., Liu, J., Rouwkema, J., de Boer, J., & van Blitterswijk, C. (2008) · European Cells and Materials · doi:10.22203/ecm.v015a03 · Cited by 168
Angiogenesis in epithelian ovarian cancer
Bamberger, E. S., & Perrett, C. W. (2002) · Molecular Pathology · doi:10.1136/mp.55.6.348 · Cited by 168
Imaging angiogenesis and the microenvironment
FUKUMURA, D., & JAIN, R. K. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01148.x · Cited by 162
“Intravital microscopy has provided useful insights into angiogenesis and tumor biology (1, 20, 128, 129).”
BackgroundSelf-citationXu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
“The angiogenic pathway targeted might be insufficient because an advanced tumor may use multiple pathways for blood vessel formation (3).”
BackgroundSelf-citationIdentification of campesterol from Chrysanthemum coronarium L. and its antiangiogenic activities
Choi, J., Lee, E., Lee, H., Kim, K., Ahn, K., Shim, B., Kim, N., Song, M., Baek, N., & Kim, S. (2007) · Phytotherapy Research · doi:10.1002/ptr.2189 · Cited by 157
Guo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164
“constitutes an important point in the control of cancer progression and a target to inhibit further growth.(47)”
BackgroundSun, Y., Chen, W., Torphy, R. J., Yao, S., Zhu, G., Lin, R., Lugano, R., Miller, E. N., Fujiwara, Y., Bian, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8922 · Cited by 174
“INTRODUCTION Abnormal vasculature is a key pathological feature facilitating tumor outgrowth and metastasis (1, 2).”
BackgroundTomographic Fluorescence Mapping of Tumor Targets
Montet, X., Ntziachristos, V., Grimm, J., & Weissleder, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0382 · Cited by 175
“, perfused) vascular volume per unit area (32).”
BackgroundMorphological Characteristics of the Microvasculature in Healing Myocardial Infarcts
Ren, G., Michael, L. H., Entman, M. L., & Frangogiannis, N. G. (2002) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540205000108 · Cited by 165
“(J Histochem Cytochem 49:71–79, 2002) A ngiogenesis follows a well-orchestrated sequence of events leading to a phase of vascular maturation and remodeling (Carmeliet and Collen 1997; Folkman 1997; Brown et al. 1998; Carmeliet 2000; Carmeliet and Jain 2000; Liekens et al. 2001).”
BackgroundNing, J., Liu, T., Dong, P., Wang, W., Ge, G., Wang, B., Yu, Z., Shi, L., Tian, X., Huo, X., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b12136 · Cited by 167
Kallistatin is a new inhibitor of angiogenesis and tumor growth
Miao, R. Q., Agata, J., Chao, L., & Chao, J. (2002) · Blood · doi:10.1182/blood-2002-01-0185 · Cited by 166
“Perfusion analyses were performed under anesthesia: (1) before surgery, (2) immediately after surgery, and at (3) 3 days, (4) 7 days, and (5) 14 days after surgery.”
MethodA review of mathematical models for the formation of vascular networks
Scianna, M., Bell, C. G., & Preziosi, L. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2013.04.037 · Cited by 167
“A natural question to ask is how do the cells feel the presence of other cells? What is the mechanism underlying intercellular crosstalk? In this regard, recent research clearly confirms that ECs exchange signals during vasculogenesis by the release and absorption of specific chemical morphogens (such as vascular endo…”
BackgroundInfluentialCascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology
Karagiannis, G. S., Pavlou, M. P., & Diamandis, E. P. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.09.001 · Cited by 159
Mechanical Forces in Tumor Angiogenesis
Zanotelli, M. R., & Reinhart-King, C. A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-95294-9_6 · Cited by 153
Endothelial cells in tumor microenvironment: insights and perspectives
Leone, P., Malerba, E., Susca, N., Favoino, E., Perosa, F., Brunori, G., Prete, M., & Racanelli, V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1367875 · Cited by 167
Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues
Chidlow, J. H., Shukla, D., Grisham, M. B., & Kevil, C. G. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00107.2007 · Cited by 167
“It has been suggested that the angiogenic components of these diseases contribute to and exacerbate disease conditions (26, 31).”
BackgroundAntiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist
Dobrzanski, P., Hunter, K., Jones-Bolin, S., Chang, H., Robinson, C., Pritchard, S., Zhao, H., & Ruggeri, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3430-2 · Cited by 160
A new era of cancer phototherapy: mechanisms and applications
Wang, Y., Ma, K., Kang, M., Yan, D., Niu, N., Yan, S., Sun, P., Zhang, L., Sun, L., Wang, D., et al. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00708e · Cited by 172
Evidence of a leading role for VEGF in Bartonella henselae-induced endothelial cell proliferations
Kempf, V. A. J., Volkmann, B., Schaller, M., Sander, C. A., Alitalo, K., Rieß, T., & Autenrieth, I. B. (2001) · Cellular Microbiology · doi:10.1046/j.1462-5822.2001.00144.x · Cited by 162
Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
Mitchell, A., Adams, L. A., MacQuillan, G., Tibballs, J., vanden Driesen, R., & Delriviere, L. (2008) · Liver Transplantation · doi:10.1002/lt.21417 · Cited by 162
“These genes are involved in the transforming growth factor- signaling pathway, which is a potent stimulator of VEGF production.9 Thus, blocking VEGF represents a logical therapeutic target for HHT. Bevacizumab is a humanized recombinant monoclonal antibody against VEGF.”
BackgroundInfluentialZhou, Y., Ren, X., Hou, Z., Wang, N., Jiang, Y., & Luan, Y. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00480d · Cited by 165
Pan, B., Shen, J., Cao, J., Zhou, Y., Shang, L., Jin, S., Cao, S., Che, D., Liu, F., & Yu, Y. (2015) · Scientific Reports · doi:10.1038/srep16053 · Cited by 165
Molecular determinants of human uveal melanoma invasion and metastasis
Seftor, E. A., Meltzer, P. S., Kirschmann, D. A., Pe'er, J., Maniotis, A. J., Trent, J. M., Folberg, R., & Hendrix, M. J. C. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015591624171 · Cited by 165
“These genes and their regulators (Ets, c-jun) have been shown to play integral roles in angiogenesis and vasculogenesis, in both normal developmental events and tumorigenesis requiring neovascularization [59–66].”
BackgroundHypoxia-induced Angiogenesis during Carcinogenesis
Choe, G.-S., Bae, M.-G., Jeong, J.-W., Mun, H.-E., & Kim, G.-W. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.120 · Cited by 165
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Vinay, D. S., & Kwon, B. S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.283 · Cited by 165
Saraswathy, M., & Gong, S. (2014) · Materials Today · doi:10.1016/j.mattod.2014.05.002 · Cited by 163
Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment
Ansiaux, R., Baudelet, C., Jordan, B. F., Beghein, N., Sonveaux, P., De Wever, J., Martinive, P., Grégoire, V., Feron, O., & Gallez, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.743.11.2 · Cited by 163
Effect of Silibinin on the Growth and Progression of Primary Lung Tumors in Mice
Singh, R. P., Deep, G., Chittezhath, M., Kaur, M., Dwyer-Nield, L. D., Malkinson, A. M., & Agarwal, R. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj231 · Cited by 165
Hajitou, A., Grignet‐Debrus, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C. F., Bajou, K., Fong, T., Chiang, Y., Foidart, J., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0109fje · Cited by 165
“The importance of the angiogenic switch for tumor progression led to a particular interest of cancer research on angiogenic activators and inhibitors that control tumor neovascularization (5, 6).”
BackgroundAngiogenesis in multiple myeloma
Jakob, C., Sterz, J., Zavrski, I., Heider, U., Kleeberg, L., Fleissner, C., Kaiser, M., & Sezer, O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.017 · Cited by 162
De Wever, O., Westbroek, W., Verloes, A., Bloemen, N., Bracke, M., Gespach, C., Bruyneel, E., & Mareel, M. (2004) · Journal of Cell Science · doi:10.1242/jcs.01322 · Cited by 160
“The best characterized mechanism is the hypoxia-dependent angiogenic switch in which host-cellderived endothelial cells invade into the tumor stroma to form new blood vessels (Carmeliet and Jain, 2000).”
BackgroundBioprinting of Multiscaled Hepatic Lobules within a Highly Vascularized Construct
Kang, D., Hong, G., An, S., Jang, I., Yun, W., Shim, J., & Jin, S. (2020) · Small · doi:10.1002/smll.201905505 · Cited by 164
Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
Fonsatti, E., & Maio, M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-18 · Cited by 164
Vascular development: from precursor cells to branched arterial and venous networks
Eichmann, A., Yuan, L., Moyon, D., Lenoble, F., Pardanaud, L., & Breant, C. (2005) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041941ae · Cited by 164
“The blood-vascular system is affected by numerous pathologies, including artherosclerosis and cancer, the two major causes of death in developed countries (Carmeliet and Jain, 2000; Cines et al., 1998; Ferrara and Alitalo, 1999; Folkman, 1995, for reviews).”
Zeng, H., Qin, L., Zhao, D., Tan, X., Manseau, E. J., Van Hoang, M., Senger, D. R., Brown, L. F., Nagy, J. A., & Dvorak, H. F. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051523 · Cited by 164
“After interaction with VEGF-A, endothelial cells undergo extensive reprogramming of protease, integrin, and glucose transporter expression; are stimulated to migrate and divide; and are protected from apoptosis and senescence (4, 5).”
BackgroundHypoxia and lymphangiogenesis in tumor microenvironment and metastasis
Ji, R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.001 · Cited by 166
“Hypoxia regulates the reciprocal production and expression of ET-1 and NO in LECs, which affects leukocyte adhesion to lymphatic wall and extravasation, and alters lymphatic tone and contractile activity [19,20].”
BackgroundInfluentialMicroscopic analysis and significance of vascular architectural complexity in renal cell carcinoma.
Sabo, E., Boltenko, A., Sova, Y., Stein, A., Kleinhaus, S., & Resnick, M. B. (2001) · PubMed · Cited by 164
Benckert, C., Jonas, S., Cramer, T., von Marschall, Z., Schäfer, G., Peters, M., Wagner, K., Radke, C., Wiedenmann, B., Neuhaus, P., et al. (2003) · PubMed · Cited by 185
Calcium Phosphates and Angiogenesis: Implications and Advances for Bone Regeneration
Malhotra, A., & Habibovic, P. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.005 · Cited by 163
Kurtoglu, M., Maher, J. C., & Lampidis, T. J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1714 · Cited by 163
“Low intratumoral oxygen resulting from attenuated blood flow due to poor or aberrant vasculature or both (5, 15) within certain areas of tumors is known to occur in more than a third of all cancers (29).”
Shinriki, S., Jono, H., Ota, K., Ueda, M., Kudo, M., Ota, T., Oike, Y., Endo, M., Ibusuki, M., Hiraki, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0287 · Cited by 163
Constitutive and inducible expression and regulation of vascular endothelial growth factor
Xie, K., Wei, D., Shi, Q., & Huang, S. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.04.003 · Cited by 163
“While little is currently known about the molecular regulation leading to constitutive VEGF expression, it is apparent that the genetic makeup of tumor cells is most probably involved in constitutive VEGF expression by affecting the production and function of transcriptional regulators [128].”
BackgroundInfluentialFibulins 3 and 5 Antagonize Tumor Angiogenesis In vivo
Albig, A. R., Neil, J. R., & Schiemann, W. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4096 · Cited by 163
“Tumor angiogenesis comprises a complex cascade of gene expression and repression that culminates in tumor neovascularization, which facilitates cancer cell proliferation, survival, and ultimately enhances cancer morbidity by establishing an escape route for metastatic cancer cells (4, 5, 22).”
BackgroundWang, D., Xu, Z., Yu, H., Chen, X., Feng, B., Cui, Z., Lin, B., Yin, Q., Zhang, Z., Chen, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.094 · Cited by 163
Endothelial cells: From innocent bystanders to active participants in immune responses
Al-Soudi, A., Kaaij, M. H., & Tas, S. W. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.008 · Cited by 152
“stimulates EC differentiation and proliferation [14].”
Olsen, C. L., Hsu, P.-P., Glienke, J., Rubanyi, G. M., & Brooks, A. R. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-43 · Cited by 179
“Angiogenesis has been well-characterized as a prerequisite to continued tumor growth and metastasis [16,17,32], and many approaches have been developed to attempt to control the progression of cancer by inhibiting angiogenesis [32,33].”
BackgroundHigh-frequency color flow imaging of the microcirculation
Goertz, D. E., Christopher, D. A., Yu, J. L., Kerbel, R. S., Burns, P. N., & Foster, F. S. (2000) · Ultrasound in Medicine & Biology · doi:10.1016/s0301-5629(99)00101-5 · Cited by 163
Sudhakar, A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24813 · Cited by 162
RetractedSakuma, K., Aoki, M., & Kannagi, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111135109 · Cited by 162
Metronomic chemotherapy and immunotherapy in cancer treatment
Chen, Y.-L., Chang, M.-C., & Cheng, W.-F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.040 · Cited by 162
Fernando, N. T., Koch, M., Rothrock, C., Gollogly, L. K., D'Amore, P. A., Ryeom, S., & Yoon, S. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4126 · Cited by 162
“It is well understood that tumor angiogenesis is regulated by a balance between proangiogenic and antiangiogenic factors (3).”
BackgroundDepleted Dopamine in Gastric Cancer Tissues
Chakroborty, D., Sarkar, C., Mitra, R. B., Banerjee, S., Dasgupta, P. S., & Basu, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0059 · Cited by 162
Potent Angiogenesis Inhibition by the Particulate Form of Fullerene Derivatives
Meng, H., Xing, G., Sun, B., Zhao, F., Lei, H., Li, W., Song, Y., Chen, Z., Yuan, H., Wang, X., et al. (2010) · ACS Nano · doi:10.1021/nn100448z · Cited by 162
“cer growth inhibition is to suppress these angiogenic factors.(2,3) Great progress has”
BackgroundInterstitial Fluid Flow and Drug Delivery in Vascularized Tumors: A Computational Model
Welter, M., & Rieger, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070395 · Cited by 158
“Moreover functional lymphatics which would normally drain the superfluous fluid are absent in most tumors aggravating the IFP increase [2].”
Gene Therapy for Malignant Glioma: Current Clinical Status
Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161
Rahman, S., Patel, Y., Murray, J., Patel, K. V., Sumathipala, R., Sobel, M., & Wijelath, E. S. (2005) · BMC Cell Biology · doi:10.1186/1471-2121-6-8 · Cited by 161
“Background The generation and repair of blood vessels in adult life requires the regulation of endothelial cell survival, migration, proliferation and their differentiation from lineagecommitted progenitors by the coordinated action of several classes of vaso-active agents including growth factors, cytokines, and the…”
Background3D Bioprinting of Vascularized Tissues for in vitro and in vivo Applications
Chen, E. P., Toksoy, Z., Davis, B. A., & Geibel, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.664188 · Cited by 161
“When examining the printed tissue’s physiological needs, we see that the limit of diffusion for O2 in tissue is generally accepted to be limited to 100–200 μm (Krogh, 1919; Carmeliet and Jain, 2000; Jain et al., 2005).”
BackgroundStem-Like Ovarian Cancer Cells Can Serve as Tumor Vascular Progenitors
Alvero, A. B., Fu, H.-H., Holmberg, J., Visintin, I., Mor, L., Marquina, C. C., Oidtman, J., Silasi, D.-A., & Mor, G. (2009) · Stem Cells · doi:10.1002/stem.191 · Cited by 161
Biological Effects of Proton Radiation: What We Know and Don't Know
Girdhani, S., Sachs, R., & Hlatky, L. (2013) · Radiation Research · doi:10.1667/rr2839.1 · Cited by 161
“The formation of new blood vessels (angiogenesis) represents a fundamental process in both the development and progression of cancers and, as such, strongly modulates the carcinogenesis process (94).”
BackgroundKunz‐Schughart, L. A., & Knuechel, R. (2002) · PubMed · doi:10.14670/hh-17.599 · Cited by 161
Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?
Murphy, M. P., Wang, H., Patel, A. N., Kambhampati, S., Angle, N., Chan, K., Marleau, A. M., Pyszniak, A., Carrier, E., Ichim, T. E., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-45 · Cited by 161
“Similarly, in cancer angiogenesis, it is known that several tumor-derived angiogenic factors synergize for acceleration of neovascularization [25].”
BackgroundHypoxia-Inducible Factor-1α Expression in Macrophages Promotes Development of Atherosclerosis
Aarup, A., Pedersen, T. X., Junker, N., Christoffersen, C., Bartels, E. D., Madsen, M., Nielsen, C. H., & Nielsen, L. B. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307830 · Cited by 151
“The thickness of lesions in the aortas of hyperlipidemic mice is normally less than the assumed oxygen diffusion distance in tissue (100–200 μm).(13) Therefore, hypoxia more likely has resulted from increased cellular oxygen consumption by macrophages and foam cells, rather than impaired oxygen delivery.”
BackgroundThe systemic treatment of recurrent ovarian cancer revisited
Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martín, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 181
“Angiogenesis is one of the hallmarks of cancer, and neo-angiogenesis is abundantly present in ovarian cancer.[53, 54] Enhancement of tumour responses has been seen when cytotoxic drugs are combined with bevacizumab, a widely used anti-angiogenic in ovarian cancer.”
BackgroundFranchi, A., Gallo, O., Massi, D., Baroni, G., & Santucci, M. (2004) · Cancer · doi:10.1002/cncr.20454 · Cited by 177
“It has been suggested that the lymphatic vessels play only a passive role during this process and lymphatic invasion occurs when tumor cells infiltrate preexisting peritumoral lymphatics.(1) However, recent evidence suggests that the formation of tumor-associated lymphatic vessels plays an active role in the metastati…”
BackgroundHB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways
Mehta, V. B., Besner, G. E., Mehta, V. B., & Besner, G. E. (2007) · Growth Factors · doi:10.1080/08977190701773070 · Cited by 158
Inflammatory cells and chemokines sustain FGF2-induced angiogenesis
Presta, M., Andrés, G., Leali, D., Dell'Era, P., & Ronca, R. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0155 · Cited by 156
“Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions, including embryonic development, wound repair, inflammation, and tumor growth [1].”
BackgroundAngiopoietin-Related/Angiopoietin-Like Proteins Regulate Angiogenesis
Oike, Y., Yasunaga, K., & Suda, T. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04034 · Cited by 160
Bernardi, R. J., Johnson, C. S., Modzelewski, R. A., & Trump, D. L. (2002) · Endocrinology · doi:10.1210/endo.143.7.8887 · Cited by 160
Metadata
- Authors
- Carmeliet, P., & Jain, R. K.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Harvard University (US)
- ORCID
- Carmeliet, Peter
- Venue
- Nature
- Published
- 2000-09
- Volume
- 407
- Issue
- 6801
- Pages
- 249-257
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1573363574
- Cited by
- 9,070
- References
- 72
- Citations by year
- 2026: 166 · 2025: 208 · 2024: 246 · 2023: 330 · 2022: 335 · 2021: 381 · 2020: 368 · 2019: 349 · 2018: 375 · 2017: 380 · 2016: 378 · 2015: 364 · 2014: 414 · 2013: 412 · 2012: 416
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- pathological angiogenesis, cancer, ischemic diseases, inflammatory diseases, anti-angiogenic therapy, clinical trials
- MeSH terms
- Animals, Disease, Humans, Lymphokines, Neoplasms, Neovascularization, Pathologic, Endothelial Growth Factors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.